65626-23-5

Basic information

• Product Name: (TETRAHYDRO-PYRAN-4-YL)-ACETALDEHYDE
• Synonyms: TETRAHYDRO-2H-PYRAN-4-YLACETALDEHYDE;(TETRAHYDRO-PYRAN-4-YL)-ACETALDEHYDE;TETRAHYDROPYRANYL-4-ACETALDEHYDE;2-(TETRAHYDRO-2H-PYRAN-4-YL)ACETALDEHYDE;(Tehrahydro-pyran-4-yl)-acetaldehyde;2-(oxan-4-yl)acetaldehyde;4-Tetrahydropyranylacetaldehyde
• CAS NO: 65626-23-5
• Molecular Formula: C₇H₁₂O₂
• Molecular Weight: 128.17
• Mol File: 65626-23-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 205.7°C at 760 mmHg
• Flash Point: 81.6°C
• Appearance: /
• Density: 0.968g/cm³
• Vapor Pressure: 0.247mmHg at 25°C
• Refractive Index: 1.429
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: (TETRAHYDRO-PYRAN-4-YL)-ACETALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: (TETRAHYDRO-PYRAN-4-YL)-ACETALDEHYDE(65626-23-5)
• EPA Substance Registry System: (TETRAHYDRO-PYRAN-4-YL)-ACETALDEHYDE(65626-23-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• Hazardous Substances Data: 65626-23-5(Hazardous Substances Data)

Usage

General Description

(Tetrahydro-pyran-4-yl)-acetaldehyde is a chemical compound with the molecular formula C7H12O2. It is a derivative of pyran and acetaldehyde and is commonly used in the field of organic synthesis. (TETRAHYDRO-PYRAN-4-YL)-ACETALDEHYDE is a colorless liquid with a slightly sweet odor and is used in the production of pharmaceuticals, perfumes, and flavorings. It is also known for its use as a building block in the synthesis of various organic compounds, and it has potential applications in the development of new materials and chemicals. Additionally, it is important to note that (tetrahydro-pyran-4-yl)-acetaldehyde may have certain health and safety considerations, and proper precautions should be taken when handling and using this chemical.

InChI:InChI=1/C7H12O2/c8-4-1-7-2-5-9-6-3-7/h4,7H,1-3,5-6H2

Upstream product

• 85064-61-5 2-(tetrahydro-2H-pyran-4-yl)acetic acid 
• 130312-00-4 ethyl tetrahydro-4H-pyran-4-ylideneacetate 
• 103260-44-2 ethyl tetrahydropyran-4-acetate 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 4677-18-3 2-(tetrahydropyran-4-yl)-ethanol 

Downstream Products

• 1607458-03-6 benzyl 3-(4-(2-oxoethyl)tetrahydro-2H-pyran-4-yl)-2-phenylpropanoate 
• 1334712-80-9 1-(4-fluorophenyl)-3-(oxan-4-yl)-1H-pyrrolo[2,3-c]pyridine 
• 1312018-43-1 1-(1-benzenesulfonyl-5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)-2-(tetrahydro-pyran-4-yl)-ethanol 
• 1312016-63-9 5-methoxy-2-[2-(tetrahydro-pyran-4-yl)-1(R)-(4-trifluoromethyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridine 
• 1312021-10-5 5-methoxy-2-[2-(tetrahydro-pyran-4-yl)-1(S)-(4-trifluoromethyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors

ATAD2 is a cancer-associated protein whose bromodomain has been described as among the least druggable of its class. In our recent disclosure of the first chemical probe against this bromodomain, GSK8814 (6), we described the use of a conformationally constrained methoxy piperidine to gain selectivity over the BET bromodomains. Here we describe an orthogonal conformational restriction strategy of the piperidine ring to give potent and selective tropane inhibitors and show structural insights into why this was more challenging than expected. Greater understanding of why different rational approaches succeeded or failed should help in the future design of selectivity in the bromodomain family.

Dihydropyrrolopyridine inhibitors of ROR-gamma

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions co

AZAINDOLE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.